基础医学与临床 ›› 2008, Vol. 28 ›› Issue (2): 128-132.

• 研究论文 • 上一篇    下一篇

RGZ对PPARgamma在裸小鼠移植瘤内表达的调控研究

吴良洪 程南生 杨帆 熊先泽 魏大鹏 夏庆杰   

  1. 四川大学华西医院 四川大学华西医院 四川大学华西医院 四川大学华西医院 四川大学基础医学与法医学院
  • 收稿日期:2006-12-13 修回日期:2007-03-27 出版日期:2008-02-25 发布日期:2008-02-25
  • 通讯作者: 程南生

The effect of PPAR-γ ligand RGZ on expression in transplantation tumor of Cholangiocarcinoma

Liang-hong WU, Nan-sheng CHENG, Fan YANG, Xian-ze XIONG, Da-peng WEI, Qing-jie XIA   

  1. Department of General Surgery, West China Hospital ,Sichuan University
  • Received:2006-12-13 Revised:2007-03-27 Online:2008-02-25 Published:2008-02-25
  • Contact: Nan-sheng CHENG,

摘要: 【摘要】目的:探讨RGZ对PPARgamma在裸小鼠移植瘤内表达的调控作用。方法:采用不同浓度和剂量的RGZ对荷瘤裸小鼠进行灌胃干预3W后处死,RT-PCR实时荧光定量检测目的基因PPAR-γ的△Ct值和表达拷贝数,测量各组瘤体体积TV和重量TW,计算相对肿瘤体积RTV、相对肿瘤增值率T/C%,并进行统计学分析。结果:胆管癌移植瘤随RGZ剂量增高,PPAR-γ的表达升高,相对肿瘤增值率T/C%减少。统计学处理,对照组与低剂量组比较,P>0.05,无统计学意义;而与高剂量组比较,P<0.001,有显著的统计学意义。结论:RGZ对PPAR-γ在裸小鼠移植瘤内能呈剂量依赖性地上调其表达,具有较强的调控作用。

关键词: 过氧化物酶体增殖物激活受体-γ, 罗格列酮, 胆管癌

Abstract: abstract objective: to study the effect of PPAR- ligand RGZ on expression in transplantation tumor of Cholangiocarcinoma . Method: interfere the nude mice bearing cancer of Cholangiocarcinoma with RGZ in different concentration and dosages, sacrificed them after 3 week intragastric administration. Measure the tumor volumes and weights, evaluate the relative tumor volume, relative tumor increasing ratio T/C%; detect the expression of PPAR-冏 by RT-PCR by Real Time Fluorescent Quantitation, statistic analysis as well. Result: following the dose of RGZ raising the expression of PPAR-, while the tumor volumes, weights , the relative tumor increment ratio T/C% decrease in the transplantation tumor of Cholangiocarcinoma. Statistic treatments show there is no significance between control and low dose groups, P>0.05; but comparing with high dose group there is obvious significance, P<0.001. Conclusionin vivo,the RGZ can show obvious effect of up-regulation PPAR- expression in transplantation tumor of Cholangiocarcinoma .

Key words: peroxisome proliferactor-activated receptor gamma, PPAR-γ, rosiglitazone, RGZ, Cholangiocarcinoma